Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
Targeting deadly drug-resistant acinetobacter infections
Highlights potential for at-home heart attack risk assessment, offering a new approach to reducing treatment delays
DST-backed researchers from Pune demonstrate targeted gene-silencing approach that significantly inhibits tumor growth with minimal toxicity
Day-care model aimed at providing specialized psychological support for women during pregnancy and motherhood
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
Subscribe To Our Newsletter & Stay Updated
